Immunoassays for the incretin hormones GIP and GLP-1

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 4, 2009, Pages 425-432

  Deacon, Carolyn F ^a   Holst, Jens J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

dipeptidyl peptidase 4 (DPP 4); enzyme linked immunosorbent assay (ELISA); glucagon like peptide 1 (GLP 1); glucose dependent insulinotropic polypeptide (GIP); incretin; radioimmunoassay (RIA)

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLICENTIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 2; OXYNTOMODULIN; PROGLUCAGON;

AMINO ACID SEQUENCE; ENZYMATIC DEGRADATION; GENE EXPRESSION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; IMMUNOASSAY; INSULIN LIKE ACTIVITY; PANCREAS ISLET BETA CELL; RELIABILITY; REVIEW; SEQUENCE HOMOLOGY;

CROSS REACTIONS; DIPEPTIDYL PEPTIDASE 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; PROGLUCAGON; RADIOIMMUNOASSAY;

EID: 69849101787     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2009.03.006     Document Type: Review

References (38)

1. Baggio L.L., and Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007) 2131-2157
2. Holst J.J. The physiology of glucagon-like peptide 1. Physiological Reviews 87 (2007) 1409-1439
3. Creutzfeldt W. The incretin concept today. Diabetologia 16 (1979) 75-85
4. Holst J.J., and Bersani M. Assays for peptide products of somatostain gene expression. Methods in Neurosciences 5 (1991) 3-22
5. Bell G.I., Santerre R.F., and Mullenbach G.T. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302 (1993) 716-718
6. Rouille Y., Westermark G., Martin S.K., et al. Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 3242-3246
7. Zhu X., Zhou A., Dey A., et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proceedings of the National Academy of Sciences of the United States of America 99 (2002) 10293-10298
8. Ugleholdt R., Zhu X., Deacon C.F., et al. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology 145 (2004) 1349-1355
9. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry 214 (1993) 829-835
10. Deacon C.F., Johnsen A.H., and Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. The Journal of Clinical Endocrinology and Metabolism 80 (1995) 952-957
11. Deacon C.F., Nauck M.A., Toft-Nielsen M., et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44 (1995) 1126-1131
12. Dai H., Gustavson S.M., Preston G.M., et al. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. Diabetes, Obesity & Metabolism 10 (2008) 506-513
13. Vilsboll T., Krarup T., Deacon C.F., et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 (2001) 609-613
14. Deacon C.F., Plamboeck A., Møller S., et al. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. American Journal of Physiology. Endocrinology and Metabolism 282 (2002) E873-E879
15. Meier J.J., Gethmann A., Nauck M.A., et al. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. American Journal of Physiology. Endocrinology and Metabolism 290 (2006) E1118-E1123
16. Elahi D., Egan J.M., Shannon R.P., et al. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring) 16 (2008) 1501-1509
17. Nikolaidis L.A., Elahi D., Shen Y.T., et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. American Journal of Physiology. Heart and Circulatory Physiology 289 (2005) H2401-H2408
18. Sonne D.P., Engstrøm T., and Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regulatory Peptides 146 (2008) 243-249
19. Ban K., Noyan-Ashraf M.H., Hoefer J., et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117 (2008) 2340-2350
20. Orskov C., Wettergren A., and Holst J.J. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42 (1993) 658-661
21. Kreymann B., Williams G., Ghatei M.A., et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 (1987) 1300-1304
22. Hendrick G.K., Gjinovci A., Baxter L.A., et al. Glucagon-like peptide-I-(7-37) suppresses hyperglycemia in rats. Metabolism 42 (1993) 1-6
23. Ørskov C., Rabenhøj L., Wettergren A., et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43 (1994) 535-539
24. Holst J.J., Bersani M., Johnsen A.H., et al. Proglucagon processing in porcine and human pancreas. The Journal of Biological Chemistry 269 (1994) 18827-18833
25. Gutniak M.K., Juntti-Berggren L., Hellstrom P.M., et al. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 19 (1996) 857-863
26. Holst J.J., and Deacon C.F. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48 (2005) 612-615
27. Hupe-Sodmann K., McGregor G.P., Bridenbaugh R., et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regulatory Peptides 58 (1995) 149-156
28. Plamboeck A., Holst J.J., Carr R.D., et al. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48 (2005) 1882-1890
29. Inagaki N., Seino Y., Takeda J., et al. Gastric inhibitory polypeptide: structure and chromosomal localization of the human gene. Molecular Endocrinology 3 (1989) 1014-1021
30. Ugleholdt R., Poulsen M.L., Holst P.J., et al. Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. The Journal of Biological Chemistry 281 (2006) 11050-11057
31. Deacon C.F., Nauck M.A., Meier J., et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 3575-3581
32. Deacon C.F., Plamboeck A., Rosenkilde M.M., et al. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. American Journal of Physiology. Endocrinology and Metabolism 291 (2006) E468-E475
33. Krarup T., and Holst J.J. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regulatory Peptides 9 (1984) 35-46
34. Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocrine Reviews 9 (1988) 122-134
35. Ørskov C., Jeppesen J., Madsbad S., et al. Proglucagon products in the plasma of non-insulin dependent diabetics and nondiabetic controls in the fasting state and following oral glucose and intravenous arginine. The Journal of Clinical Investigation 87 (1991) 415-423
36. Ahrén B., Landin-Olsson M., Jansson P.A., et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 2078-2084
37. Herman G.A., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clinical Pharmacology & Therapeutics 78 (2005) 675-688
38. Theodorakis M.J., Carlson O., Muller D.C., et al. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 27 (2004) 1692-1698